Auspex Pharmaceuticals

Auspex Pharmaceuticals ($ASPX)
La Jolla, CA
IPO price: $12
Close Sept. 30: $25.67
Change: Up 114%
Raised: $84 million

Scoop: Auspex was among the biotech test cases of early 2014, swinging for a $76 million IPO as industry watchers were unsure whether 2013's bull market would carry over into the new year. Turns out it did, and Auspex pulled off an upsized offering at the top of its range, establishing a floor for its soaring shares. The company's lead candidate is SD-809, a VMAT-2 inhibitor for movement disorders, and Auspex is in the midst of a Phase III study on abnormal involuntary movements associated with Huntington's disease, planning to file with the FDA this year for a potential 2015 launch. At the same time, Auspex is plotting a Phase IIb trial of the drug in tardive dyskinesia and is soon to launch a Phase Ib study to see whether SD-809 can treat tics associated with Tourette syndrome.

For more:
Three biotechs haul in $242M in up-sized IPOs as the industry's boom endures
Auspex's $76M IPO pitch tests the limits of biotech's window

Auspex Pharmaceuticals

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.